We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$322M
AUM Growth
-$34.8M
Cap. Flow
-$3.33M
Cap. Flow %
-1.03%
Top 10 Hldgs %
62.73%
Holding
76
New
14
Increased
20
Reduced
18
Closed
19
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$14.9M
2
GSK icon
GSK
GSK
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
4
NVST icon
Envista
NVST
+$8.88M
5
DXCM icon
DexCom
DXCM
+$6.92M

Top Sells

Rank Stock Value
1
RCM icon
R1 RCM Inc. Common Stock
RCM
+$23.3M
2
EHTH icon
eHealth
EHTH
+$12.3M
3
RDUS icon
Radius Health, Inc.
RDUS
+$8.96M
4
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.38M
5
NUVA
NuVasive, Inc.
NUVA
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 90.47%
2 Real Estate 4.59%
3 Industrials 2.01%
4 Communication Services 1.04%
5 Miscellaneous 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BDSI
26
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.98M 0.92%
708,020
+351,746
+99% +$1.5M
2019 Q2
1 quarter
ARQL
27
DELISTED
Arqule Inc
ARQL
$2.96M 0.92%
412,388
-39,300
-9% -$369K
2018 Q2
5 quarters
HSKA
28
DELISTED
Heska Corp
HSKA
$2.89M 0.9%
40,824
+5,900
+17% +$443K
2019 Q1
2 quarters
EHTH icon
29
eHealth
EHTH
$18.8M
$2.85M 0.88%
42,653
-136,086
-76% -$12.3M
2019 Q1
2 quarters
AMRN icon
30
CALL
Amarin Corp
AMRN
$239M
$2.44M 0.76%
+8,055
New +$2.81M
2019 Q3
0 quarters
CYH icon
31
Community Health Systems
CYH
$406M
$2.19M 0.68%
+607,383
New +$1.58M
2019 Q3
0 quarters
FATE icon
32
Fate Therapeutics
FATE
$214M
$2.18M 0.68%
140,656
-77,200
-35% -$1.48M
2018 Q4
3 quarters
CYTK icon
33
Cytokinetics
CYTK
$8.61B
$2.07M 0.64%
+181,700
New +$2.28M
2019 Q3
0 quarters
TCDA
34
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.02M 0.63%
65,568
-22,000
-25% -$737K
2018 Q3
4 quarters
MGNX icon
35
MacroGenics
MGNX
$207M
$1.98M 0.61%
154,824
-35,799
-19% -$516K
2019 Q2
1 quarter
XENE icon
36
Xenon Pharmaceuticals
XENE
$3.24B
$1.94M 0.6%
215,609
-8,731
-4% -$82.6K
2018 Q3
4 quarters
APLS icon
37
DELISTED
Apellis Pharmaceuticals
APLS
$1.92M 0.59%
79,509
-37,800
-32% -$1.04M
2018 Q2
5 quarters
BCRX icon
38
BioCryst Pharmaceuticals
BCRX
$1.99B
$1.88M 0.58%
654,460
+312,000
+91% +$970K
2017 Q4
7 quarters
COLL icon
39
Collegium Pharmaceutical
COLL
$755M
$1.84M 0.57%
160,295
+19,295
+14% +$220K
2019 Q2
1 quarter
SCPH icon
40
DELISTED
scPharmaceuticals
SCPH
$1.3M 0.4%
221,636
+47,339
+27% +$267K
2019 Q2
1 quarter
AGRX
41
DELISTED
Agile Therapeutics
AGRX
$1.08M 0.33%
+455
New +$1.12M
2019 Q3
0 quarters
IVC
42
DELISTED
Invacare Corporation
IVC
$970K 0.3%
129,361
-80,922
-38% -$454K
2017 Q4
7 quarters
AFMD icon
43
DELISTED
Affimed
AFMD
$947K 0.29%
32,217
– –
2018 Q1
6 quarters
OTIC
44
DELISTED
Otonomy, Inc.
OTIC
$899K 0.28%
376,342
+181,913
+94% +$433K
2019 Q1
2 quarters
CDXS icon
45
Codexis
CDXS
$136M
$864K 0.27%
+63,000
New +$991K
2019 Q3
0 quarters
SVRA icon
46
Savara
SVRA
$914M
$839K 0.26%
316,679
+74,536
+31% +$186K
2019 Q2
1 quarter
DCPH icon
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$747K 0.23%
22,000
-283,233
-93% -$8.38M
2018 Q4
3 quarters
OPTN icon
48
DELISTED
OptiNose
OPTN
$736K 0.23%
7,007
– –
2019 Q2
1 quarter
EIGR
49
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$715K 0.22%
2,324
– –
2019 Q1
2 quarters
DRNA
50
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$590K 0.18%
41,074
– –
2018 Q2
5 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Eversept Partners held 76 positions worth $322M, down 9.7% from $357M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners's Q3 2019 filing shows 14 new, 20 increased, 18 reduced and 19 closed positions. Its largest new stake was Envista: 318,000 shares worth $8.87M. The largest sale was R1 RCM Inc. Common Stock, an estimated $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Real Estate and Industrials.

  • Eversept Partners's largest Q3 2019 buy was Envista: 318,000 shares worth $8.87M.
  • Eversept Partners added most to The Ensign Group in Q3 2019, an estimated $14.9M increase.
  • Eversept Partners's biggest Q3 2019 reduction was R1 RCM Inc. Common Stock, cutting an estimated $23.3M.
  • Eversept Partners fully exited NuVasive, Inc. in Q3 2019, selling an estimated $5.37M.
  • Eversept Partners's ten largest holdings make up 63% of its $322M portfolio in Q3 2019.
  • Eversept Partners opened 14 new positions and closed 19 in Q3 2019.
  • Eversept Partners's portfolio value fell 9.7% quarter-over-quarter to $322M.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.